The multivalent conjugates are completely resistant to serine protease PRSS degradation secreted by cetuximab‐resistant tumor cells and trigger a stronger Fc‐mediated immunity through the engagement of endogenous anti‐Rha antibodies both in vitro and in vivo. This evidence concerns the gene DHX9 and neoplasm.